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Background: Aromatase inhibitors (AIs) are widely used as an adjuvant endocrine treatment in postmenopausal
women with early-stage breast cancer. One of the main adverse effects of AIs is musculoskeletal symptoms, which
leads to a lower quality of life and poor adherence to AI treatment. To date, no effective management of aromatase
inhibitor-associated musculoskeletal symptoms (AIMSS) has been developed.
Methods/design: To determine whether the traditional Chinese medicine Yi Shen Jian Gu granules could effectively
manage AIMSS we will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients
experiencing musculoskeletal symptoms after taking AIs will be enrolled and treated with traditional Chinese medicine
or placebo for 12 weeks. The primary outcome measures include Brief Pain Inventory-Short Form, Western Ontario and
McMaster Universities Osteoarthritis Index, and Modified Score for the Assessment and Quantification of Chronic
Rheumatoid Affections of the Hands, which will be obtained at baseline and at 4, 8, 12 and 24 weeks.
Discussion: The results of this study will provide a new strategy to help relieve AIMSS.
Trial registration: ISCTN: ISRCTN06129599 (assigned 14 August 2013).
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Third-generation aromatase inhibitors (AIs; that is, ana-
strozole, letrozole and exemestane) have become the
standard of care for the adjuvant treatment of hormone-
responsive breast cancer in postmenopausal women. For
many years, tamoxifen was the cornerstone of endocrine
therapy [1]. However, recent clinical trials of AIs have
shown benefits over tamoxifen. The main advantages are
improvement of disease-free survival, decreased rates of
contralateral breast cancer and a more favorable toxicity
profile, with lower rates of thromboembolic phenomena
and endometrial malignancy [2-8]. These trials reported
incidences of musculoskeletal symptoms ranging from
5% to 35%. Observational studies, however, have shown* Correspondence: wangxiaomin_bhtcm@126.com
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unless otherwise stated.that aromatase inhibitor-associated musculoskeletal symp-
toms (AIMSS) are more prevalent than originally reported
[9,10]. In a cross-sectional survey of 200 women receiving
adjuvant AI therapy for breast cancer, 94 (47%) reported
AI-associated joint pain, and 88 (44%) reported joint
stiffness; nearly 13% of patients discontinued therapy
because of intolerable musculoskeletal symptoms [9].
Because the mechanisms mediating AIMSS are not
clearly understood, effective management of AIMSS has
not yet been developed.
Potential interventions for AIMSS usually include non-
steroidal anti-inflammatory drugs, analgesics, calcitriol
agents, vitamin D, and exercise. Some patients even have
to switch AIs or switch to tamoxifen because of severe
musculoskeletal symptoms [11,12]. However, it is not clear
whether any of these interventions have had a dramatic ef-
fect on musculoskeletal symptoms. Therefore, due to the
unsatisfactory response to current symptomatic treatments,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cine (TCM).
TCM, which has a unique advantage in alleviating
symptoms and improving quality of life, has been widely
applied in China for the treatment of cancer-related side
effects, such as nausea, vomiting, fatigue, tidal fever, and
pain [13,14]. Postmenopausal women with AIMSS exhibit
a specific pathological change associated with deficiency
of kidney essence and depression of liver qi, according to
TCM theory [15]. Insufficient kidney essence results in
failure to nourish the related body constituents and or-
gans, including bone and joints. Liver qi depression leads
to stagnation of qi movement, manifested as pain [16].
Through prescription of Yi Shen Jian Gu granules (YSJG),
which, according to therapeutic principle of TCM, would
tonify the kidney, fortify the bone, soothe the liver, regu-
late qi and unblock the collateral, we noted that AIMSS
could be partly relieved in clinical practice. YSJG has been
commonly used in our hospital for the treatment of mus-
culoskeletal symptoms, including bone pain, myalgia, and
arthralgia, in patients with osteoporosis or arthrosis. How-
ever, useful empirical observation is insufficient. There-
fore, there is a need for a well-designed clinical trial to
investigate the efficacy and safety of YSJG on AIMSS. The
results of this study will provide clinical evidence on the
efficacy and safety of YSJG in patients with AIMSS.
Methods/design
Study design
This study is a multicenter, randomized, double-blind,
placebo-controlled clinical trial with two parallel arms
(Figure 1). The aim of the study is to evaluate whether
TCM (YSJG) is effective to relieve AIMSS in patients
with breast cancer. Eighty-four participants will be re-
cruited from three centers: Beijing Hospital of Traditional
Chinese Medicine affiliated with Capital Medical University,
Beijing Cancer Hospital, and Guang’Anmen Hospital affil-
iated with China Academy of Chinese Medical Sciences.
All participants will be prescribed one of the following
AIs: anastrozole (Arimidex, AstraZeneca Pharmaceutical
Co., 587 Old Baltimore Pike, Newark, Delaware, 19702,
USA; 1 mg/day), letrozole (Femara, Novartis Pharma
Schweiz AG, Schaffhauserstrasse 4332 Stein, Switzerland,
or Letrozole Tablets, Jiang Su Heng Rui Medicine Co.,
Ltd, No 38, the Yellow River Road, Lianyungang City,
Jiangsu Province; 2.5 mg/day), or exemestane (Aromasin,
Pfizer Inc., Localita Marino del Tronto 63100, Italy;
25 mg/day). After a 2-week run-in period, eligible partici-
pants will be randomly assigned to the TCM group or the
placebo group. Considering that the majority of postmen-
opausal women who are taking AI need to receive calcium
and vitamin D, and in order to maintain the homogeneity
between patients, we will prescribe calcium carbonate and
vitamin D3 tablets for all participants (each tablet iscomprised of 600 mg calcium and 125 IU vitamin D3; par-
ticipants take two tablets daily for 12 weeks; Wyeth
Pharmaceutical Co. Ltd, No 4, Baodai West Road, Suzhou
City, Jiangsu Province). The TCM group will receive YSJG
granules, and the placebo group will receive placebo gran-
ules. Both groups will have a 12-week treatment period
and a 12-week follow-up period. Five visits will be sched-
uled for each patient in their respective centers: one visit
each at weeks 0, 4, 8, 12, and 24.
Ethical issues
The trial will be conducted in accordance with the Declar-
ation of Helsinki and the Ethical Guidelines for Clinical
Research, and the trial protocol has been approved by the
Research Ethical Committee of Beijing Hospital of Trad-
itional Chinese Medicine Affiliated with Capital Medical
University (ref: 201337). This trial was registered with
ISRCTN at Current Controlled Trials (ISRCTN06129599).
Study participants
Participants will be recruited from three hospitals (Beijing
Hospital of Traditional Chinese Medicine, Beijing Cancer
Hospital, and Guang’Anmen Hospital) by poster and web-
site advertisements. Informed consent will be obtained
from all participants before randomization. Eligibility and
exclusion criteria are presented in Table 1.
Interventions
For the treatment group, YSJG granules are composed
of 12 herbs, including Radix rehmanniae Preparata
(ShuDiHuang), Semen cuscutae (TuSiZi), Rhizoma cyperi
(XiangFu), Rhizoma chuanxiong (ChuanXiong), Rhizoma
corydalis (YanHuSuo), Caulis trachelospermi (LuoShiTeng),
and so forth. Because the formula for YSJG is currently
being patented, the ingredients in YSJG cannot be pub-
lished at this time.
For the control group, placebo granules are made from
dextrin (95%) and Herba pogostemonis (5%) in order to
achieve the same color, smell, taste, and texture as that
of YSJG granules.
Both YSJG and placebo granules were manufactured
by Beijing Tcmages Pharmaceutical Co. Ltd (No 5, Niu
Hui Street, Shun Yi District, Beijing) according to the
standards of Good Manufactoring Practice. Patients will
be instructed to dissolve a sachet of granules (12.4 g) in
200 mL hot water and to take the solution orally twice a
day for 12 weeks.
Randomization and blinding
Block randomization was carried out in a 1:1 ratio accord-
ing to the sequence generated with SAS (Version 7.0;
Channel-leadian pharmaceuticals R&D, Co., Ltd; No 19,
Xiao Ying Road, Chao Yang District, Beijing). Drug codes,
numbered from 1 to 84, and contained group assignments
Figure 1 Project overview. 1BPI-SF: Brief Pain Inventory-Short Form (Chinese version). 2WOMAC 3.1 Index: Western Ontario and McMaster Universities
Osteoarthritis Index (Chinese version). 3M-SACRAH: Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of
the Hands (Chinese version). 4FACT-B: the Functional Assessment of Cancer Therapy breast cancer-specific quality of life tool (Chinese version).
5BMD: bone mineral density. 6Safety assessment: blood routine test, urine routine test, feces routine test, kidney function test, liver function test,
estradiol (E2), follicle-stimulating hormone, tumor markers (CEA, CA125, and CA153). AIMSS, aromatase inhibitor-associated musculoskeletal
symptoms; TCM, traditional Chinese medicine; YSJG, Yi Shen Jian Gu granules.
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Eligible patients will be randomized into the YSJG group
or the placebo group by obtaining medicines associated
with the given drug codes in accordance with the order of
visits. Group assignments will not be revealed until the
entire study is completed. Participants, investigators, stat-
isticians, and all study staff are blinded.
Outcome measures
Primary outcome measure
As pain is the most common complaint of AIMSS, we
selected the Brief Pain Inventory-Short Form (BPI-SF)
as the primary outcome measure to evaluate general
pain. The BPI-SF, created by the Pain Research Group,is a 14-item questionnaire to measure both the intensity
of pain as well as the interference of pain in the patient’s
life on a scale ranging from 0 to 10.Secondary outcome measures
Quality of life instruments The Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
is a patient-reported outcome measure for assessing
osteoarthritis of the knees or hips. It consists of 24 ques-
tions (5 pain, 2 stiffness, and 17 physical function) and can
be completed in less than 5 minutes. We selected the
WOMAC index to assess joint pain, stiffness, and func-
tional status in the knees.
Table 1 Eligibility criteria
Inclusion criteria
1. Pathologically confirmed stage I to III breast cancer with no
recurrence and metastasis.
2. Completed chemotherapy and/or radiotherapy.
3. Currently using a third-generation aromatase inhibitor (anastrozole,
letrozole, or exemestane) and self-reported ongoing musculoskeletal
symptoms (arthralgia and/or stiffness and/or swelling in one or more
joints, bone pain, myalgia, carpal tunnel syndrome, trigger finger),
which started or worsened after initiation of aromatase inhibitor
therapy and has continued for more than 1 month, and who had a
baseline worst pain score over the past week on the Brief Pain
Inventory-Short Form ≥3 points on a scale of 0 to 10.
4. Eastern Cooperative Oncology Group performance status 0-2.
5. Provided written informed consent before enrollment.
Exclusion criteria
1. Patients with endocrine and any other diseases influencing bone
metabolism (for example, hyperthyroidism, hypothyroidism, diabetes,
Cushing’s syndrome, chronic liver disease, nephropathy, myeloma,
bone tumor, or bone metastasis).
2. Used of agents influencing bone metabolism (for example,
glucocorticoid, thyroid hormone, heparin, anticonvulsants, diuretics,
or bisphosphonates), except calcium agents, within the past 3
months.
3. Contraindications to calcium agents and vitamin D.
4. Diagnosed with primary osteoarticular diseases.
5. Presence of other primary tumors and severe heart, liver, kidney, and
hematopoietic system diseases.
6. Presence of pregnancy, mental illness, or cognitive handicap.
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cation of Chronic Rheumatoid Affections of the Hands
(M-SACRAH) consists of three domains assessing pain,
stiffness, and functional status in patients suffering from
hand osteoarthritis and rheumatoid arthritis, answered
on 100-mm visual analog scales. We selected the M-
SACRAH to assess joint pain, stiffness, and functional
status in the hands.
The Functional Assessment of Cancer Therapy-Breast
(FACT-B), a quality of life instrument to assess the well-
being of cancer patients, measures physical, social/family,
emotional, and functional well-being as well as additional
concerns commonly reported in breast cancer patients.
The FACT-B scale has five response levels (ranging from
‘not at all’ to ‘very much’). Changes in the scores on these
scales before and after intervention will be compared be-
tween the TCM group and the placebo group.
Bone mineral density Musculoskeletal symptoms and
bone loss are identified as the two main adverse effects of
AIs. One study reported a correlation between AIMSS
and osteoporosis (bone fractures) [17]. In order to investi-
gate the effects of YSJG on bone loss, bone mineral dens-
ity (BMD) of the L2-L4 region of the spine and hip will be
assessed before and after treatment (at weeks 0 and 12).Safety assessments
In order to assess the safety of YSJG, we will perform
the following tests on all participants at the screening
phase (week 0) and after treatment (week 12): blood routine
test, urine routine test, feces routine test, kidney function
test, liver function test, estradiol (E2), follicle-stimulating
hormone, and serum levels of tumor markers (CEA,
CA125, and CA153). In addition, investigators will ask
every subject at each visit whether they have experi-
enced any adverse events (AEs) during the study period.
If there are any AEs, the investigator will provide appro-
priate treatment to the subject immediately and record
AEs in a dedicated document in the case report form,
including its severity and causality with the experimen-
tal agent. In the case of serious adverse events (SAEs),
the investigator will offer appropriate treatment to the
subject immediately and report the event to the Institu-
tional Review Board within 24 hours from the time of
recognition. If necessary, blinding will be broken by ad-
equate procedure, and the documented procedure will
be kept in the investigator study file.
Sample size calculation
As there has been no similar TCM research on AIMSS
to date, we calculated sample size according to another
AIMSS study that used the same primary outcome
measure (BPI-SF) [18]. From the results of this previous
study, the treatment group had a reduction of 1.5 points
(the standard deviation was 2.1) on the mean BPI-SF
worst pain compared with the control group. Therefore,
34 participants per group were deemed sufficient to achieve
90% power and a (one-sided) 5% significance level in de-
tecting treatment differences. Considering a total with-
drawal and dropout rate of 20%, we concluded that a
total of 84 patients (42 per arm) would need to be re-
cruited to ensure statistically significant results.
Statistical analysis
Efficacy and safety analyses will be conducted according
to the intention-to-treat principle. Missing values will be
imputed by the last-observation-carried-forward method.
All statistical analyses will be performed using Statistical
Packages of Social Sciences software (SPSS 18.0, Channel-
leadian pharmaceuticals R&D, Co., Ltd; No 19, Xiao Ying
Road, Chao Yang District, Beijing). Statistical significance
will be defined as a one-sided P-value of <0.05. Demo-
graphic, clinical, and outcome variables will be described
using means and standard deviations for continuous
variables and percentages for categorical variables. The
primary analysis will be to compare the mean pain
scores from BPI-SF, the WOMAC, and the M-SACRAH
and the mean joint stiffness and function scores from
the WOMAC and the M-SACRAH between the TCM
group and the placebo group. The secondary analysis
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changes in BMD before and after treatment. Student’s
t-tests and repeated-measure analyses of variance with
a time-interaction term will be used to compare group
differences.
Data collection and monitoring
This is a 24-week clinical trial, in which participants need
to take research medication for 12 weeks, accept a 12-week
follow-up, attend five assessment visits, obtain two sets of
laboratory tests (safety assessments) and BMD analysis, fill
in four sets of questionnaires at each visit, and stop taking
other herbal medications (Table 2).
Beijing Qihuang Medicine Clinical Research Center is
responsible for quality control. Censors have regular
visits (once a month) to monitor protocol violations, the
recruitment rate, AEs and participant compliance.
Discussion
Up to half of patients on AI therapy experience muscu-
loskeletal symptoms, and up to 20% will discontinue
therapy because of intolerable side effects; therefore,
AIMSS has become an important clinical issue requiring
effective management.
Effective management of AIMSS is still a mystery in
clinical practice, as the mechanisms behind AIMSS are
not clearly understood. A number of small interven-
tional trials investigating acupuncture [19,20], vitamin D
[18], glucosamine [21], short-term low-dose prednisol-
one [22], thymosin α1 [23], duloxetine [24] and yogaTable 2 Data collection schedule
Screening Treatment Follow-up
Visit number 1 2 3 4 5





BPI-SF ✘ ✘ ✘ ✘ ✘
WOMAC ✘ ✘ ✘ ✘ ✘
M-SACRAH ✘ ✘ ✘ ✘ ✘
FACT-B ✘ ✘ ✘ ✘ ✘
Bone mineral density ✘ ✘
Safety assessment ✘ ✘
Combined medication ✘ ✘ ✘ ✘ ✘
Adverse events ✘ ✘ ✘ ✘
Compliance ✘ ✘ ✘
AIMSS, aromatase inhibitor-associated musculoskeletal symptoms; BPI-SF, Brief
Pain Inventory-Short Form; ECOG, Eastern Cooperative Oncology Group; FACT-B,
The Functional Assessment of Cancer Therapy-Breast; M-SACRAH, Modified Score
for the Assessment and Quantification of Chronic Rheumatoid Affections of the
Hands; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.[25] have provided various treatment strategies. How-
ever, most of these trials have had some methodological
and practical limitations, including small sample sizes,
larger-than-anticipated drop-out, a single-center design,
lack of control group and blinding, and a short follow-up
period. Therefore, developing appropriate management
strategies for AIMSS will require further investigation. To
date, there is still a lack of prospective, randomized, con-
trolled trials to provide powerful evidence supporting the
use of various treatment modalities. Our study will be the
first randomized, double-blind, placebo-controlled clinical
trial analyzing the efficacy and safety of TCM in patients
with AIMSS.
There are several limitations to our study. One limi-
tation is the absence of specific measures for AIMSS.
AIMSS is a set of symptoms involving the bone, muscles
and joints. There are no questionnaires specially designed
for AIMSS. Through reviewing the literature and reported
studies [20,23,26], rheumatological questionnaires may be
validated in the longitudinal assessment of joint symp-
toms, although the pathological processes are likely to be
different. We selected WOMAC and M-SACRAH that
focus on joint pain, stiffness, and functional status in the
hands and knees, which are the most common locations
of pain. Another limitation is the indeterminate diagnostic
criteria of AIMSS. Musculoskeletal symptoms are reported
according to different terms (for example, arthralgia, joint
symptoms, joint pain, and musculoskeletal symptoms) in
the literature. Because of the lack of clear diagnostic cri-
teria, various clinical trials have reported a wide range of
AIMSS incidence and research objects, which confuses
physicians and investigators and makes it challenging to
recognize the manifestations of AIMSS and to establish
acceptable inclusion criteria. In order to clear the clinical
characteristics of AIMSS and inclusion criteria, we defined
AIMSS, through reviewing the literature [10,11,27,28], as
self-reported ongoing musculoskeletal symptoms, includ-
ing arthralgia, joint stiffness, joint swelling, bone pain, my-
algia, carpal tunnel syndrome, and trigger finger, which
started or worsened after taking an AI.
The results of this study will provide a new evidence-
based treatment strategy for patients suffering from
AIMSS.Trial status
The trial is currently enrolling participants.
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